Nomlabofusp: Molecular Structure

Molecular Structure#

Nomlabofusp (CTI-1601) is a recombinant fusion protein designed to deliver functional human frataxin to mitochondria. It represents a pioneering application of cell-penetrating peptide (CPP) technology as a drug delivery platform for protein replacement therapy.

Fusion Protein Architecture#

The protein consists of three functional domains arranged N-terminal to C-terminal:

1. TAT cell-penetrating peptide: The sequence M-YGRKKRRQRRR, derived from the HIV-1 trans-activator of transcription protein transduction domain. This highly cationic sequence (net charge +8 at physiological pH) enables membrane translocation
2. Diglycine (Gly-Gly) linker: A short flexible linker connecting the CPP to the frataxin cargo, minimizing steric interference between the two functional domains
3. Full-length human frataxin: Including the native mitochondrial targeting sequence (MTS) and complete mature frataxin protein (amino acids 81-210)

Physical Properties#

Cell Entry and Mitochondrial Delivery#

Cell Penetration Mechanism#

The TAT CPP enables nomlabofusp to cross cell membranes through a combination of:

• Direct translocation: Electrostatic interaction between the cationic TAT sequence and anionic membrane phospholipids
• Macropinocytosis: Cellular uptake of extracellular material
• Non-receptor-mediated: Unlike many biologics, CPP-mediated entry does not require specific cell-surface receptors, enabling broad tissue distribution

Mitochondrial Import and Processing#

After cell entry, nomlabofusp undergoes sequential processing:

1. The MTS (mitochondrial targeting sequence) within the frataxin portion directs the fusion protein to the mitochondrial import machinery (TOM/TIM complex)
2. The protein is translocated into the mitochondrial matrix
3. Mitochondrial processing peptidase (MPP) cleaves the protein at the natural cleavage site between MTS and mature frataxin
4. The CPP and MTS fragments are released and degraded
5. Mature frataxin (14.3 kDa) is released as the functional end product

Critically, the MPP cleavage site is the same site used by endogenous frataxin precursor, meaning the mature protein produced is identical to native mature frataxin.

Frataxin: The Target Protein#

Frataxin is a nuclear-encoded, mitochondrial protein essential for:

• Iron-sulfur cluster (ISC) assembly: Frataxin serves as an iron chaperone for the ISC assembly machinery, which produces essential cofactors for complexes I, II, and III of the electron transport chain
• Cellular energy production: Through ISC-dependent respiratory chain function
• Iron homeostasis: Regulation of mitochondrial iron and prevention of iron-mediated oxidative damage
• Oxidative stress protection: By facilitating proper electron transport chain function and iron handling

In Friedreich ataxia, GAA repeat expansion in the FXN gene leads to heterochromatin-mediated transcriptional silencing, reducing frataxin levels to 5-30% of normal. This deficiency causes progressive degeneration of dorsal root ganglia, spinocerebellar tracts, and cardiac tissue.

Pharmacokinetics#

The rapid plasma peak (15 minutes) and short plasma half-life reflect rapid tissue distribution of the fusion protein. The pharmacodynamic effect (frataxin accumulation in tissues) is cumulative with daily dosing, with carrier-equivalent levels achieved after approximately 6 months.

Comparison with Other FA Therapeutic Approaches#

Stability Considerations#

As a recombinant protein, nomlabofusp has specific stability requirements:

• Cold chain storage (2-8 degrees C) required
• Susceptible to proteolytic degradation if improperly handled
• Must be protected from light
• Cannot be frozen
• Limited shelf life compared to small molecules

Related Reading#

• Nomlabofusp overview and research guide
• Peptides similar to nomlabofusp
• Nomlabofusp research evidence